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Abstract In 2015, five or more biosimilars may be
approved in the USA. Because no two biologic medicines
are identical, postapproval safety monitoring will be criti-
cal to detect potential differences in safety signals between
a biosimilar, its reference product, and other biosimilars.
Postapproval safety monitoring in the USA uses two signal
detection systems: spontaneous reporting systems (SRSs)
and active surveillance (AS) systems. Both depend on
accurate identification of the specific product(s) dispensed
or administered to patients, which may be compromised
when products from multiple manufacturers share common
drug nomenclature or coding. Product identification can
present challenges across different healthcare settings,
including inpatient and ambulatory care. Common oral-
dosage drugs are predominantly dispensed directly to
patients by pharmacists, whereas most injectable drugs,
including biologics, are administered to patients by
healthcare professionals in outpatient clinics or hospitals.
Thus, the effectiveness of SRS and AS mechanisms in both
pharmacy and medical channels must be given greater
consideration as biotechnology matures. In this article, we
describe these systems and their limitations. We identify
challenges and opportunities for product-specific safety
surveillance of biologics in both the pharmacy and medical
settings and provide recommendations to improve biologic
safety surveillance under the current and future systems
envisioned in the Drug Quality and Security Act. As
biosimilars are integrated into existing pharmacovigilance
systems, distinguishable nonproprietary names and codes
for all biologics, as well as other opportunities to improve
traceability (e.g., increased use of barcodes), must be
considered to ensure patient safety and confidence in this
new class of drugs.
Key Points
Postapproval safety monitoring for biologic products
relies on both active surveillance (AS) and
spontaneous reporting systems (SRSs), and these
must be effective for biologics dispensed both in the
pharmacy and through medical benefit channels.
Both SRS and AS approaches rely on accurate
identification of the product(s) dispensed or
administered to patients, and the effectiveness of
these surveillance methods may be compromised
when there are multiple manufacturers for products
that share common drug nomenclature or coding.
Federal, state, and health information technology
policies that promote complete, accurate, and
accessible tracking of dispensing data in patient
medical records are essential to ensure traceability of
outcomes for biologic products. These should
include, but not be limited to, the application of
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2015 marks an important milestone in the maturity of
medical biotechnology, with five or more biosimilar
applications pending review by the US Food and Drug
Administration (FDA). For the first time, a number of
manufacturers will produce a series of highly similar but
not identical medicines for the US market. The first
biosimilar (Zarxio [filgrastim-sndz]) was approved in the
USA in March 2015, indicating that this new era has begun
[1]. Accordingly, it will be important that pharmacovigi-
lance systems are able to detect differences between
adverse events (AEs) associated with a biosimilar and AEs
associated with its reference product [2–4]. Given the
structural and manufacturing complexities of biologics and
the potential for structural differences between biosimilars
and their reference products, the paradigm currently
applied for monitoring of drug safety with small-molecule
generic drugs is insufficient for biologics, including
biosimilars [5]. Long-term patient safety monitoring of
biologics is required to properly evaluate the immunogenic
effects of both new and established biologics in the market
[6]. Postapproval surveillance for immunogenicity and rare
AEs may be needed; they may not be apparent during
preapproval testing, because of the relatively small patient
populations evaluated [2]. Moreover, it is important that
the specific biologic or manufacturer is readily identified to
ensure accurate tracing of AEs to the administered product
[7]. Increased use of barcodes on biologic drugs should
improve tracing capabilities, as should implementation of
the US Drug Quality and Security Act/Drug Supply Chain
Security Act (DQSA/DSCSA), which outlines use of an
interoperable electronic system to identify and trace pre-
scription drugs in the USA [8].
The objectives of this article are (1) to describe the
spontaneous reporting systems (SRSs) and active surveil-
lance (AS) systems used in the USA and their limitations;
(2) to inform regulators, physicians, and pharmacists about
the pharmacovigilance challenges for biologics from mul-
tiple manufacturers that have similar active substances;
(3) to describe the difficulties of product traceability in
hospital and physician office settings—the predominant
settings for the administration of biologics; (4) to describe
challenges and opportunities to improve product-specific
safety surveillance of biologics dispensed to patients in
retail or mail-order pharmacy settings; and (5) to encour-
age improvements in the traceability and pharmacovigi-
lance of biologics in the USA by making recommendations
for policies and practices that may improve the fidelity of
SRSs and AS systems, targeting those recommendations
toward the settings where these pharmacovigilance systems
are used.
2 USA Pharmacovigilance and Biologics
In the USA, postapproval safety signal detection is per-
formed primarily using SRS and AS systems [9, 10]. The
attributes of each of these systems can be complementary
for biologics from multiple manufacturers that have similar
active substances, provided that AEs are properly linked to
a specific product.
SRSs (e.g., MedWatch and institution-based reporting)
are considered passive surveillance methods, which rely
on voluntary reports from physicians, pharmacists, other
healthcare providers, and patients [11]. AS methods
include retrospective analysis of medical records at
Sentinel-affiliated sites and drug or disease registries, as
well as use of drug event monitoring (e.g., surveys of
patients identified through electronic prescription data)
[12]. SRSs are important for identification of safety
signals, including potential rare AEs not identified during
clinical trials or premarketing studies [10]. For products
(such as biologics) that are relatively sensitive to man-
ufacturing conditions, SRSs may be useful for detection
of emergent safety signals associated with changes in
product quality throughout the life cycle of the medicine.
A limitation of SRS approaches is that they cannot
accurately quantify the incidence of identified risks for a
given product, because the total number of patients
treated with the drug is unknown [10, 13]. AS methods
can identify new safety signals [14] but are better suited
to assess the incidence and severity of identified risks
[10]. AS systems, when used as a method to identify
new safety signals, often derive multiple potential links,
necessitating development of algorithms that are
informed by and integrated with clinical and scientific
assessment to further prove causality; the SRS and other
sources may be used to prespecify potential AEs of
interest [15].
Both SRS and AS approaches rely on accurate identifi-
cation of the product(s) dispensed or administered to
patients, and the effectiveness of these surveillance meth-
ods may be compromised when there are multiple manu-
facturers of products that share common drug
nomenclature or coding [4]. Furthermore, product identi-
fication can present unique challenges across different
healthcare settings, including inpatient and ambulatory
care. Common oral-dosage drugs are predominantly dis-
pensed directly to patients by pharmacists (i.e., via the
pharmacy benefit channel), whereas most injectable drugs,
including biologics, are administered to patients by
healthcare professionals in outpatient clinics or hospitals,
as covered under the medical benefit. Thus, it is essential to
account for the effectiveness of SRS and AS mechanisms
in both the pharmacy and medical channels.
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2.1 USA MedWatch Spontaneous Reporting System
Spontaneous surveillance occurs through reports to the
manufacturer and to the FDA MedWatch program. Physi-
cians, pharmacists, other healthcare providers, and patients
can voluntarily submit reports of serious reactions, product
quality problems, and therapeutic failure, through a Med-
Watch reporting form [11]. Indeed, according to a pub-
lished analysis of suspected drug reaction reports on
biopharmaceutical products in the FDA Adverse Event
Reporting System (FAERS) database (from 2004 to 2010),
patients were identified as the reporter in 41 % of reports,
prescribers or other healthcare providers in 36 % of
reports, and pharmacists in only 3 % of reports [16]. SRSs
rely on the accuracy of the information submitted, and, on
the basis of the distribution of likely reporters of AEs, it is
not sufficient that the pharmacist is the only member of the
care team who has ready access to complete records
identifying the drugs administered.
Under the FDA’s current system, MedWatch reports can
be submitted with minimal product identification. In brief,
these reports include the following data: an identifiable
patient, an identifiable reporter, a suspect drug or biologic
product, and an AE or fatal outcome [17]. Reports may
contain only a nonproprietary active ingredient name;
therefore, drugs with the same nonproprietary name will
typically be grouped together for pharmacovigilance pur-
poses [18]. The FDA’s manual of policies and procedures
titled Handling of Adverse Experience Reports and Other
Generic Drug Postmarketing Reports stipulates that
‘‘generally, OGD [the Office of Generic Drugs] receives
few AERs [adverse experience reports] or similar reports
since the reports may not specify a generic manufacturer
for the drug product. Furthermore, the safety profile of a
particular drug is usually well-known before generic ver-
sions are approved. Therefore, AERs associated with a
generic drug are less likely to be reported’’ [18]. Although
the MedWatch form advises that the manufacturer name
should be reported when the nonproprietary name is used,
the FDA has indicated that the manufacturer name is
included in only 3 % of reports, and the associated data
field was therefore removed from the FAERS database in
2000 [19].
A further complication of the pharmacovigilance of
biologics is that for delayed immunologic reactions—in
particular, those caused by formation of anti-drug anti-
bodies—there may be a considerable time lag between
administration of the biologic and the appearance of a
serious reaction [20]. This time lag may make it difficult
to attribute the event to a specific product in a case in
which a patient has been switched between related bio-
logics. A delayed immune response may also affect the
ability to attribute the AE to a specific lot of a biologic
product if a comprehensive medication history is not
accessible [3, 21]. In these circumstances, the SRS would
be inadequate for identifying manufacturer- or batch-as-
sociated issues with biologics. However, with modifica-
tions as described below, SRS AE reports could also be a
means of achieving early identification of batch- or pro-
duct-specific problems. In a pharmacovigilance environ-
ment, with multiple manufacturers selling products with
similar active substances, it is critical that product iden-
tification is supported by robust and, if possible, redun-
dant product-specific identifiers. There are two case
studies that may have direct implications for AE reporting
in SRSs after biosimilars are introduced in the USA [22,
23].
In the first case study, an analysis of the FAERS
demonstrated that for six of the eight drugs evaluated, the
number of monthly AE reports attributed to the originator
brand product did not decrease significantly when generic
competition became available, although there was a steep
decrease in the number of dispensed prescriptions of the
originator drug [22]. This suggests that AEs may have been
attributed to the wrong product through use of the origi-
nator brand name in SRS reports, when it is possible that
the patients received a generic product [22].
The limitations of the existing US SRSs that can com-
promise an efficient and expeditious investigation are
exemplified in a second case study of 246 death reports
potentially associated with contaminated heparin adminis-
tration between January 2007 and May 2008 [24]. The US
Government Accountability Office report on the FDA’s
management of the heparin contamination crisis indicated
that, on review of 94 death reports, only 13 of the reports
included heparin lot numbers, and 28 of the 46 voluntary
reports did not identify the heparin manufacturer. There-
fore, it was not feasible for the FDA to determine the
heparin contamination status in most of the deaths [23].
Economically incentivized adulteration of raw materials is
not a common concern for biologics, but this case study
highlights current gaps in SRSs that prevent accurate and
timely identification of an implicated product and manu-
facturer when related products from multiple manufactur-
ers are available to patients.
2.2 USA FDA’s Sentinel System and Other Sources
of Data (Active Surveillance)
AS methods are diverse, and a complete characterization of
this comprehensive area is beyond the scope of this article.
As such, our discussion is limited to retrospective database
analyses from existing systems and does not include more
expensive methods (e.g., registries, open-label long-term
studies, prospective observational studies). Retrospective
AS occurs through analysis of larger patient administrative
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data sets from healthcare institutions, laboratories, indi-
vidual healthcare providers, and/or medical claims records
[25]. As one example of AS, the FDA’s Sentinel pilot
program uses the electronic health information available in
claims systems, inpatient and outpatient healthcare records,
and patient registries to match a specific medicine (as-
suming billing codes are product specific) with a clinically
reported outcome [26]. In principle, billing and electronic
health record (EHR) databases can refer to reimbursement
codes to faithfully record claims associated with use of a
specific drug, as well as diagnosis codes linked to potential
AEs, permitting statistical linkage of therapies to patient
outcomes. Vulnerabilities include both the accuracy of
product identification as derived from claims data and, if
captured, the diagnosis coding selected by the clinician.
Pooled administrative and claims data often shed product
identifiers such as brand names when merged from dis-
parate systems, leaving only nonproprietary names or
active ingredient names connected to a patient’s medical
record. Regardless of the data source (e.g., claims, general
clinical practice, drug dispensary databases), product-
specific AS requires either specific reimbursement codes or
use of unique product names or other identifiers
(e.g., manufacturer names).
AS using medical claims data is only sensitive to bill-
able International Classification of Diseases, Ninth Edition
(ICD-9) diagnosis codes and diagnosis-related groups
(DRGs) used to link administration of a drug or biologic to
a subsequent AE. A systematic review of the Mini-Sentinel
program found limited information related to anaphylaxis-
reporting algorithms and indicated that the positive pre-
dictive value of ICD-9 codes for anaphylaxis was low
when applied to all-cause anaphylaxis [27]. There are many
nonspecific ICD-9 codes that have been used when cate-
gorizing immunologic reactions, including (but not limited
to) allergic urticaria (708.0), unspecified adverse effect of a
drug (995.2), allergy unspecified (995.3), and erythema
multiforme (695.1) [28–30]. Because many ICD-9 codes
are currently used to capture allergic and other immuno-
logic reactions, it is likely that this would also be true for
biologics, including immunologic reactions leading to a
loss of efficacy.
In a pharmacovigilance setting for biologic products
subject to biosimilar competition, an opportunity to enable
accurate attribution of an AE to a specific product may
include assignment of multiple or redundant product
identifiers to promote resilience of attribution in the event
of errors or ambiguity in any one identifier. The relative
effectiveness and utility of these product identifiers is
dependent on the settings in which the product is pre-
dominantly used and the ability of SRSs and AS systems to
accurately capture the product identity.
3 Utility and Limitations of Product Identifiers
for Biologics in Spontaneous Reporting
and Active Surveillance Systems
The five product identifiers that may be included in Med-
Watch AE reports are the brand name, nonproprietary
name, National Drug Code (NDC), manufacturer name,
and lot number [3]. Other product identifiers, such as
medical benefit reimbursement codes (Healthcare Common
Procedure Coding System [HCPCS]), may be used for AS.
The utility of each of these identifiers may be limited in
regard to their use in SRSs and limited by the healthcare
setting in which the AE reporting is performed (see
Table 1).
3.1 Brand Names
Brand names are often the primary identifiers used for
reporting AEs [3]. Approximately 50 % of 376 USA pre-
scribers who were surveyed used the brand name to iden-
tify a medicine for prescription or recording in patient
records [31]. Brand name reporting for biologics in SRSs
can vary by the product class and jurisdiction. For example,
84 % use of accurate brand names has been reported for
insulins in the USA, whereas product-specific attribution of
epoetins approached 99 % in the European Union (EU)
[16, 32]. In the EU, legislation enacted in 2010 requires
member states to take measures to ensure that trade names
are used in health records and AE reports for biological
medicinal products [33]. Despite this legislation, 21 % of
filgrastim-related spontaneous reports originating from the
EU between April 2012 and December 2014 and received
by Amgen were not attributed to a particular brand name.
Similarly, in Australia, 42 % of reports received by the
Therapeutic Goods Administration public database
between March 2011 and November 2014 were coded as
‘‘filgrastim (not specified)’’ [34]. These data indicate that a
large proportion of reporters use the nonproprietary name,
not the brand name, when reporting AEs. Brand names are
not usually found in medical benefit claims and are
unsuitable for AS, in which only billing codes are assigned
to administered products.
3.2 Nonproprietary Names
A product’s nonproprietary name (also referred to as its
generic name, established name, US Adopted Name
[USAN], International Nonproprietary Name [INN], or
active ingredient) is often used in the USA because it is not
mandatory that products receive a brand name, nor is it
mandatory that prescribers use a brand name when one is
available. A survey of community-based physician office









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pharmacovigilance Considerations for Biosimilars in the USA 313
visits in the USA revealed that the median frequency of
generic name prescribing was 21 % [35]. The nonpropri-
etary name is commonly used to identify the product in AE
reports and is acknowledged as a useful tool for pharma-
covigilance of nonbiologic drugs worldwide [3, 6].
Most nonproprietary names for drugs and biologics are
linked to the World Health Organization (WHO) INN
system. In many cases, INN naming rules would permit
sponsors to differentiate between originator biologics and
their copies through incorporation of distinct Greek letter
suffixes (e.g., ‘‘epoetin zeta’’ versus ‘‘epoetin alfa’’) when
differences in glycosylation exist. However, such a system
is voluntary, and, in practice, the INN cannot be relied on
for product-specific identification of biosimilars, because
regulators have generally permitted biosimilars to adopt the
same INN as their reference products [6, 16]. If multiple
biosimilars were licensed with a shared nonproprietary
name identical to the INN of the same reference product,
patients and physicians might be unable to distinguish
between the biologics for the purposes of AE reports. To
address this risk, the FDA has recently published draft
guidance that calls for the addition of a unique suffix to the
INN for all biologics, including biosimilars, to differentiate
products and minimize inadvertent substitution [36]. This
naming convention is similar to that proposed by the WHO
[37]. The success of a naming approach that confers
unique, distinguishable names for all biologics will be
limited by its implementation and follow-through. If
unique names are confirmed for all biosimilars, then the
naming approach will need to be accommodated and used
consistently in all settings and systems in which biologics
are prescribed, dispensed, recorded, and, if needed, repor-
ted for AEs.
3.3 National Drug Codes
NDCs are specific to each drug product but are rarely used
by physicians. For example, only 14 % of respondents to a
survey of prescribers conducted by the Alliance for Safe
Biologic Medicines indicated that they would use the NDC
or a combination of the product name and the NDC in an
AE report [31]. Moreover, NDCs are not required by fed-
eral law to appear on product labeling [38], and they are
rarely found on the labels of dispensed prescription
medicines [39]. Thus, NDCs have limited use as reliable
product identifiers to support the SRS. However, NDCs are
commonly used for reimbursement in the community
pharmacy setting and can provide accurate product iden-
tification for pharmacy benefit claims databases used in
AS. Finally, NDCs are used only in the USA and are not a
global solution for product identification.
3.4 Manufacturer Names
A field for the manufacturer name is included in the
MedWatch 3500 report form as an optional identifier for
unbranded products [40], but current pharmacovigilance
systems in the USA are not set up to capture this identifier
for nonvaccine biologic products. The MedWatch form
advises reporters to include the manufacturer name when
using a generic drug name [39, 40], but the field is used so
rarely that the FDA does not include the manufacturer
name in the FAERS database [19]. In the USA, the Vaccine
Adverse Event Reporting System (VAERS), sponsored by
the Centers for Disease Control and Prevention and the
FDA, separately tracks AEs that occur after vaccine
administration; the manufacturer name is commonly
tracked in VAERS [41, 42]. EHR systems may not include
a field for the manufacturer name, nor is it included in the
National Council for Prescription Drug Programs (NCPDP)
10.6 Script standard for medication history reports [43].
Therefore, significant changes in database structures, reg-
ulations, policies, and incentives would need to be imple-
mented to increase the use of manufacturer names for
nonvaccine biologic products in health records and safety
surveillance systems.
3.5 Lot Numbers
Lot numbers are of primary importance in assisting man-
ufacturers with connection of a safety issue to a specific lot
of a manufactured product. The lot number is the only
product identifier that can provide information for tracing
of specific manufacturing production batches [3]. Billing
data collected in hospital and physician office settings
typically do not include lot numbers [44]; therefore, lot
numbers have no utility with respect to AS. Additionally,
these data are not routinely used in the SRS; a review of the
completeness of MedWatch data indicated that lot numbers
were completed in only 9 % of the 10.2 million records
evaluated [45]. In a review of reports from FAERS and
EudraVigilance in the EU, lot numbers for biopharma-
ceuticals were provided in 24 and 21 % of reports,
respectively [16]. Batch number reporting depends on the
product class. An analysis of FAERS suspect AE reports
for insulin and somatropin products showed that lot num-
bers were available in 37 % of insulin reports but in only
13 % of somatropin reports [32].
In light of the limitations of each of these five product
identifiers, there is a need for reliable and redundant
identifiers for biologic products subject to biosimilar
competition, especially in AS systems that are designed to
capture data through analysis of health records.
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3.6 Medical Channel Reimbursement Codes
Physician office and hospital outpatient claims for drug
administration procedures commonly use HCPCS codes,
but these codes have not historically been assigned
uniquely for each new biologic [46]. Because this
channel represents the majority of therapeutic biologic
product prescriptions in the USA, such codes are par-
ticularly relevant to AS of biologics. A recent study
confirmed that claims-based data could be used to track
immunogenicity-related signals for an injectable generic
in the pharmacy setting but not for hospital or clinic use,
where all versions of the product share the same HCPCS
codes [47].
However, on July 8, 2015, the Centers for Medicare &
Medicaid Services (CMS) published in the Federal
Register a proposed rule to have all biosimilars share a
J-code [48]. Such a policy would prevent AS of biosimilar
products, allowing comparisons only between the experi-
ence with a reference product and the aggregate experience
of its biosimilars. This proposed rule goes against the
legislation establishing the biosimilar pathway in the USA,
which was supported by conforming amendments to the
Social Security Act section 1847A(b)(4),(6) that should
have prohibited reimbursement based on a volume-
weighted average [49, 50] and supported separate HCPCS
codes for each biosimilar product. If the proposed rule is
reversed and unique HCPCS codes are issued for biosim-
ilars, it may be possible to perform product-specific AS.
A small proportion of biologic therapies may be
administered in the hospital inpatient setting. Hospital
inpatient claims typically use a DRG to assign a bundled
payment according to the ICD-9 Clinical Modification
diagnosis and procedure codes [46]. With very rare
exceptions, these procedure codes are not specific to a
given biologic therapy or underlying event; therefore, they
are not useful for AS.
4 Robust Pharmacovigilance of Biologics
in the USA Must Account for the Settings of Use
To more completely evaluate and understand the current
capabilities and limitations of pharmacovigilance systems
for biologics with multiple manufacturers, it is necessary to
consider all of the settings where therapeutic biologics are
used. The majority of therapeutic biologic products are
administered by healthcare professionals in physician
offices, hospital outpatient settings, or other institutional
settings, but some biologics are distributed primarily
through retail or mail-order pharmacy channels (e.g., self-
administered therapeutics for chronic diseases such as
rheumatoid arthritis) [44].
4.1 The Outpatient Medical Channel
In the absence of a distinguishable nonproprietary name and
product-specific billing codes, health recordsmaynot include
a unique verifiable product identifier associated with a bio-
logic administered in physician offices and hospital outpa-
tient settings. The lack of distinguishable nonproprietary
names and product-specific billing codes could undermine
the effectiveness of both SRS and AS systems. If an office or
hospital pharmacy has the option to purchase similar bio-
logics from multiple sources that are assumed to be the same
because of shared nonproprietary names, there may be a lack
of transparency for the prescriberwith respect to themedicine
purchased, dispensed, and administered to the patient. This
would create confusion in the event that one biosimilar, but
not others, was associated with a particular AE.
A depiction of how an AE caused by a generic product
can be misattributed to the originator product is provided in
Fig. 1. When a generic supply of medication is introduced
into the in-house pharmacy inventory, administrative staff
may not code new identifier records in the formulary that
are specific to the generic. Instead, because the products
share the same nonproprietary names, the generic may
simply be identified in the prescription order entry and
EHR systems as if the originator brand product were being
ordered and dispensed. Failure of the EHR to include
information about the manufacturer of the generic product
actually dispensed, along with use of the originator brand
name as an alias for the generic, may result in incorrect use
of the originator brand name in AE reports.
4.2 The Pharmacy Channel
The pharmacy channel represents another potential chal-
lenge to pharmacovigilance, because dispensing transac-
tions are typically performed by an entity independent of
the prescriber, creating a potential gap in provider access to
product identifiers. This challenge is particularly acute in
the case of automatic substitution of products that are
determined to be therapeutically equivalent. In the context
of biologic medicines, many are anticipated to be approved
without a determination of interchangeability, whereas
some biosimilars may ultimately be licensed as inter-
changeable biologics that may be automatically substituted
for the prescribed reference biologic [51]. When an auto-
matic substitution is deemed scientifically appropriate, the
provider’s prescription records will be rendered either
ambiguous or inaccurate, depending on the identity of the
dispensed product. Some state pharmacy practice acts have
incorporated amendments intended to address this potential
gap. If automatic substitution of a biologic is permitted in a
given state, these provisions promote physician access to
medication history data by requiring that pharmacists enter
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product identifiers into an electronic record system acces-
sible to prescribers. In some states, the amended practice
acts may require direct communication of the dispensing
data to the prescriber by other means if such interoperable
systems are not in place. For example, a recently passed
Delaware Senate bill includes a requirement for the phar-
macist to record the name and manufacturer of a biologic
product within 10 days of dispensing the product when an
FDA-approved interchangeable biologic product is substi-
tuted for a prescribed reference biologic product. The
pharmacist must also, within 10 days, inform the pre-
scribing physician which biologic was dispensed [52]. A
similar bill was passed in Massachusetts, requiring phar-
macists to record substitution of interchangeable biologic
products in an interoperable EHR system, if available, and
to report such substitutions to the prescriber [53].
Finally, AS of biologics used in the pharmacy setting is
facilitated by use of product-specific reimbursement codes
(NDCs). This would also be the case if interchangeable
biologics are automatically substituted. Reimbursement
codes are available in the administrative claims databases
and may be linked to AE-related diagnosis codes irre-
spective of provider awareness of the specific biologic
dispensed.
5 Four Dimensions to Consider for Effective
Biologic Pharmacovigilance: Limitations
and Recommendations for Accurate Product
Identification
The scope of the challenges to improving the robustness of
SRS and AS systems for biologic products subject to
biosimilar competition is broad and encompasses both
pharmacy and institutional settings (Fig. 2). Within each of
the dimensions (i.e., combinations of pharmacovigilance
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Fig. 1 Schematic of prescription order entry and fulfillment at a US
medical institution, demonstrating how reported adverse events (AEs)
can be misattributed. When a generic supply of medication is
introduced into the in-house pharmacy inventory, administrative staff
may not introduce new identifier records specific to the generic.
Instead, the generic may be identified in the prescription order entry
and electronic health record (EHR) systems as if the originator
product were being ordered and dispensed. 2D two-dimensional, FDA
US Food and Drug Administration, USAN US Adopted Name
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mechanisms and settings of use), there are practices that
currently allow for effective pharmacovigilance monitor-
ing, as well as limitations that could hinder efforts to
effectively monitor the safety of biologic products with
multiple manufacturers.
We previously conducted a retrospective analysis to
assess the capabilities of passive and active surveillance
systems to track safety events for Lovenox (enoxaparin;
Sanofi) and generic enoxaparin—a complex, sterile
injectable drug [47]. Enoxaparin was selected as a surro-
gate for biologics and biosimilars with respect to safety
surveillance considerations because of its potential for
immunogenicity and related rare safety signals (i.e., hep-
arin-induced thrombocytopenia) and because enoxaparin is
dispensed in both retail and non-retail channels. After the
loss of exclusivity (LOE) for Lovenox, only 5 % of
spontaneous safety reports were processed by
manufacturers of generic enoxaparin, although generic
enoxaparin had rapidly captured 50 % of the market after
LOE. On the basis of the market share after LOE, reports
attributable to specific generic enoxaparin products were
roughly ninefold lower than expected. Insurance claims
data supported useful AS of enoxaparin dispensed under a
pharmacy benefit but not under a medical benefit. These
results suggest that current safety surveillance systems do
not sufficiently distinguish product-specific safety signals
for drugs distributed by multiple manufacturers, including
generics and biosimilars.
Because pharmacists have access to all required data on
the drug dispensed, AE reporting via the SRS should work
in the pharmacy setting, provided that other stakeholders
(e.g., prescribers, other healthcare professionals, and
patients) can also access these data. However, the effec-
tiveness of the SRS in the pharmacy setting may be
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Fig. 2 Four dimensions to consider for effective biologic pharmacovig-
ilance. DSCSA Drug Supply Chain Security Act, EHR electronic health
record, FDA US Food and Drug Administration, HCPCS Healthcare
Common Procedure Coding System, NDC National Drug Code,
Rx prescription
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compromised because lot numbers are not available to the
prescriber, and because prescriber records may not reflect
the actual product dispensed in the case of a prescription by
nonproprietary name or an automatic pharmacy substitu-
tion, thereby limiting accurate patient and prescriber AE
reporting. In principle, medication history reports may
provide prescribers with automated access to records of
biologics dispensed in the pharmacy channel [54], but these
reports will not facilitate the SRS unless specific product
manufacturer identifiers are captured in those reports. To
address these limitations, the following policy recommen-
dations are suggested: (1) assignment of distinguishable
nonproprietary names to all biologics; (2) amendment of
standards to capture manufacturer names and lot numbers
in EHRs (similar to the inclusion of NDCs in the NCPDP
10.6 Patient Medication History Script standard) [43];
(3) MedWatch online prompts for the product brand name
(if available), nonproprietary name, manufacturer name,
and lot number for biologics; and (4) establishment of
interoperable EHRs or pharmacist-prescriber communica-
tion of dispensing transaction data that conveys product-
and manufacturer-specific information. In addition, edu-
cation of the healthcare community on the importance,
process, and best practices for reporting is also essential to
improve the quality of SRS data. This may increase the
number of rare or unexpected AEs reported while con-
currently improving the quality of AE reports.
A closed system for formulary choices for products
that are not assumed to be therapeutically equivalent and
for safety reporting can, in principle, support the SRS in
the institutional setting. The effectiveness of the SRS in
the institutional setting is limited by ambiguous capture of
product identification and the fact that lot numbers are not
captured in EHRs. To address these limitations, the fol-
lowing policy recommendations are suggested: (1) as-
signment of distinguishable nonproprietary names to all
biologics; (2) amendment of standards to capture manu-
facturer names and lot numbers in EHRs; (3) MedWatch
online prompts for the product brand name (if available),
nonproprietary name, manufacturer name, and lot number
for biologics; and (4) promotion of standards for
improved EHR fidelity with respect to the products
dispensed.
In the AS pharmacy setting, NDCs are used widely,
allowing for accurate product identification. However,
ICD-9 diagnostic codes may not be clearly defined or
consistently used for immunologic or allergic drug reac-
tions (e.g., hypersensitivity) [55], and the lack of manu-
facturer identification and lot numbers in reimbursement
claims data limits the effectiveness of AS for tracking
issues related to changes in product quality. Improvement
of diagnostic codes for immunologic reactions and pol-
icy changes to standardize the use of manufacturer
identification and lot-level data within administrative data
would increase the effectiveness of AS. This would include
efforts to improve identification and reporting of potential
immunogenicity-mediated loss of efficacy.
In the AS institutional setting, product-specific HCPCS
codes are effective when they are available and are used.
The effectiveness of AS in the institutional setting is lim-
ited when there is nonspecific product coding, inconsistent
immunologic reaction diagnosis coding, and infrequent use
of lot numbers. To address these limitations, establishment
of product-specific HCPCS codes for biologics and
improvement of diagnostic codes for immunologic reac-
tions would increase the effectiveness of AS in the insti-
tutional settings in which biologic products are primarily
administered [44]. Distinguishable nonproprietary names
may also improve attribution in claims data linked to
EHRs, even in the event that reimbursement codes are
shared or aggregated via DRGs. The EHR may include
details about the administered product in a descriptive
field. We also suggest mandatory use of NDCs and
amendment of policy standards to capture manufacturer
names and lot numbers in claims data.
6 Other Considerations for Improving Biologic
Pharmacovigilance
With the increasing use of two- and three-dimensional
barcoding, both at the bedside currently and potentially in
the future as part of the implementation of the DQSA/
DSCSA, an opportunity for improving product traceability
exists [8]. For patients who are administered a biologic, the
information currently conveyed via barcodes is typically
linked to information readily available at an institution’s
pharmacy; these data are only as rich as the information
available for transfer into a barcoding system. As such,
manual entry of long codes, batch numbers, manufacturer
names, and other information (e.g., product expiration
dates) currently prevents consistent availability and inclu-
sion of this information in barcodes and AE reports;
development of barcode product identifiers at the manu-
facturer level should standardize this type of information to
allow greater ease of AE reporting. The DQSA/DSCSA are
US federal mandates that require tracking of product
information between trade partners [8]. Federal law cur-
rently does not require use of any particular technology for
product tracing and allows paper-based records until 2017,
at which point electronic records will be required by
manufacturers; repackagers will be required to include
electronic records in 2018. Wholesalers and dispensers will
be required to only trade products with electronic identi-
fiers beginning in 2019 and 2020, respectively. However,
exemptions to this law may allow continued use of paper-
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based product tracing between manufacturers and licensed
healthcare providers [8]. Additionally, there is no mandate
for information to be available at the dose level; current
product information requirements apply only to secondary
packaging. Lastly, there is no requirement for transfer of
data elements into a patient’s medical record [8]. These
three DQSA/DSCSA gaps can be bridged in the following
ways: (1) promotion of barcode technology (e.g., GS1) as
the major method of conveying information between
partners; (2) requirements for barcodes on primary dose
packaging; and (3) adoption of standards that require
extension of rich product identifier information, conveyed
as part of the federal law, past the final custodian of a
biologic and into a patient’s medical record (see Table 2).
7 Conclusions
Multiple product-specific identifiers should be available to
reporters, who should be encouraged to include one or
more such identifiers in spontaneous safety reports. The
brand name can be one such identifier, but it is not required
for prescribing or medical benefit-related claims-based
record keeping. Also, because of the data structures of
commonly used EHRs, NDCs and lot numbers cannot be
relied on as redundant identifiers for reporters. The Euro-
pean solution of identifying products by a ‘‘trade name’’
comprising the INN and the manufacturer name (e.g., fil-
grastim Hexal) in the absence of a brand name will not
work in the USA, because a concatenation of the nonpro-
prietary name and the manufacturer name is not a recog-
nized trade name, and the separate manufacturer name field
is not commonly captured in health records or FAERS.
Distinguishable nonproprietary names provide another
retrievable identifier. The nonproprietary name is always
available in health records when a brand name is not
available or is not used, and this information could there-
fore be retrieved by a reporter for inclusion in a sponta-
neous report. As biosimilars are integrated into the existing
pharmacovigilance systems, establishment of distinguish-
able nonproprietary names for all biologics is recom-
mended to improve their traceability [36].
The biggest challenge for SRS and AS of biologics with
multiple manufacturers lies in the physician office and
hospital settings. Furthermore, substitution of products
from multiple manufacturers without accurate documen-
tation to distinguish between products will lead to inac-
curate medication histories. Distinct HCPCS codes serve
not only to implement Biologics Price Competition and
Innovation Act provisions for Part B reimbursement but
also to support application of the FDA Sentinel Initiative to
future biologics with multiple manufacturers. The use of
distinguishable nonproprietary names could also improve
traceability in these medical and hospital benefit settings,
where product identification is often homogenized to a
shared nonproprietary name.
In the long term, technology systems must advance to
ease the transfer of essential product identifier information
into patient medical records and allow for interoperable
access to this information by patients, physicians, and
pharmacists. Although several gaps remain, the changes
associated with implementation of the DQSA over the next
decade provide an opportunity to take advantage of these
technologies.
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